| Title |
Cerliponase Alfa: First Global Approval
|
|---|---|
| Published in |
Drugs, June 2017
|
| DOI | 10.1007/s40265-017-0771-8 |
| Pubmed ID | |
| Authors |
Anthony Markham |
| Abstract |
Cerliponase alfa (Brineura™) is a recombinant human tripeptidyl peptidase-1 (TTP1) being developed by BioMarin Pharmaceutical Inc. for use in patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), a paediatric neurodegenerative disease caused by a deficiency in TPP1. CLN2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. This article summarizes the milestones in the development of cerliponase alfa leading to its first global approval for the treatment of motor function loss in paediatric patients ≥3 years of age with CLN2. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 17% |
| Researcher | 11 | 15% |
| Student > Bachelor | 9 | 12% |
| Student > Doctoral Student | 6 | 8% |
| Student > Postgraduate | 5 | 7% |
| Other | 15 | 20% |
| Unknown | 16 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 23% |
| Biochemistry, Genetics and Molecular Biology | 12 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 9% |
| Agricultural and Biological Sciences | 5 | 7% |
| Neuroscience | 5 | 7% |
| Other | 11 | 15% |
| Unknown | 18 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2024.
All research outputs
#7,119,445
of 25,353,525 outputs
Outputs from Drugs
#1,231
of 3,482 outputs
Outputs of similar age
#104,380
of 323,684 outputs
Outputs of similar age from Drugs
#11
of 36 outputs
Altmetric has tracked 25,353,525 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,482 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,684 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.